Concepedia

Yanli Wu

YW

Statistics

Publications

4

Citations

312

H-Index

4

Active since

2014

Affiliations

AstraZeneca (Germany)(Current)

Yanli Wu is an author at AstraZeneca (Germany) specializing in bispecific antibodies, life sciences, and cytotoxic t-lymphocyte-associated protein 4 inhibitors.

ORCID

Publications per year

2014–2021

4

Publications

4

Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells

Simon J. Dovedi, Matthew J. Elder, Chunning Yang et al. · Cancer Discovery · 2021 · 180 citations

, , +17

pH-dependent Binding Engineering Reveals an FcRn Affinity Threshold That Governs IgG Recycling

M. Jack Borrok, Yanli Wu, Nurten Beyaz et al. · Journal of Biological Chemistry · 2014 · 103 citations · Full text

, , +16

Abstract 2776: MEDI5752: A novel bispecific antibody that preferentially targets CTLA-4 on PD-1 expressing T-cells

Simon J. Dovedi, Yariv Mazor, Matthew J. Elder et al. · Cancer Research · 2018 · 16 citations

, , +17

Fab-Arm Exchange Combined with Selective Protein A Purification Results in a Platform for Rapid Preparation of Monovalent Bispecific Antibodies Directly from Culture Media

James J. Steinhardt, Yanli Wu, Ryan Fleming et al. · Pharmaceutics · 2019 · 13 citations · Full text

, , +17

1–4 of 4